Pulmonary Artery Denervation: Update on Clinical Studies
- 42 Downloads
Purpose of Review
Sympathetic overactivity plays an important role in the progression of pulmonary arterial hypertension (PAH). The purpose of this review is to illustrate localization of pulmonary arterial sympathetic nerves, the key steps of pulmonary artery denervation (PADN) procedure, and to highlight clinical outcomes.
Sympathetic nerves mostly occurred in the posterior region of the bifurcation and pulmonary trunk. Emerging preclinical data provided the potential of PADN for PAH. PADN, produced at bifurcation area, improved a profound reduction of pulmonary arterial pressure and ameliorated clinical outcomes with an exclusive ablation catheter. The application of PADN in the patients of PAH or combined pre-capillary and post-capillary PH (CpcPH) improved the hemodynamic parameters and increased 6MWD.
Sympathetic overactivity aggravates PAH. PADN is a promising interventional treatment for PAH and CpcPH. Additional clinical trials are warranted to confirm the efficacy of PADN.
KeywordsPulmonary arterial hypertension Sympathetic nervous Pulmonary denervation Ablation Annular catheter with 10 electrodes Clinical trial
Compliance with Ethical Standards
Conflict of Interest
Hang Zhang and Shao-Liang Chen declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. https://doi.org/10.1093/eurheartj/ehv317.CrossRefPubMedGoogle Scholar
- 4.Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P, et al. Increased sympathetic nerve activity in pulmonary artery hypertension[J]. Circulation. 2004;110(10):1308–12. https://doi.org/10.1161/01.CIR.0000140724.90898.D3.CrossRefPubMedGoogle Scholar
- 11.Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation. 2015;131(23):2079–91. https://doi.org/10.1161/CIRCULATIONAHA.114.006980.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Zhou L, Zhang J, Jiang XM, Xie DJ, Wang JS, Li L, et al. Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized monocrotaline[J]. JACC Cardiovasc Interv. 2015;8(15):2013–23. https://doi.org/10.1016/j.jcin.2015.09.015.CrossRefPubMedGoogle Scholar
- 16.Rothman AM, Arnold ND, Chang W, Watson O, Swift AJ, Condliffe R, et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension[J]. Circ Cardiovasc Interv. 2015;8(11):e2569. https://doi.org/10.1161/CIRCINTERVENTIONS.115.002569.CrossRefGoogle Scholar
- 18.Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol. 2013;62(12):1092–100. https://doi.org/10.1016/j.jacc.2013.05.075.CrossRefPubMedGoogle Scholar
- 19.• Chen SL, Zhang H, Xie DJ, Zhang J, Zhou L, Rothman AM, et al. Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study[J]. Circ Cardiovasc Interv. 2015;8(11):e2837. https://doi.org/10.1161/CIRCINTERVENTIONS.115.002837. PADN was safe and feasible for the treatment of PAH. The PADN procedure was associated with significant improvements in hemodynamic function, exercise capacity, and cardiac function and with less frequent PAH-related events and death at 1 year after PADN treatment. CrossRefGoogle Scholar
- 23.Naeije R, Gerges M, Vachiery JL, Caravita S, Gerges C, Lang IM. Hemodynamic phenotyping of pulmonary hypertension in left heart failure. Circ Heart Fail. 2017;10:e004082. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004082.CrossRefPubMedGoogle Scholar
- 24.Fayyaz AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018;137(17):1796–810. https://doi.org/10.1161/CIRCULATIONAHA.117.031608.CrossRefPubMedGoogle Scholar
- 26.Hwang IC, Kim YJ, Park JB, Yoon YE, Lee SP, Kim HK, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17:150. https://doi.org/10.1186/s12872-017-0576-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.•• Zhang H, Zhang J, Chen M, Xie DJ, Kan J, Yu W, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study. JACC Cardiovasc Interv. 2019;12(3):274–84. https://doi.org/10.1016/j.jcin.2018.09.021. The trial is the first to demonstrate the benefits of PADN for patients with CpcPH. Finding suggest that PADN is associated with significant improvements in hemodynamic, cardiac function, and clinical outcomes. CrossRefPubMedGoogle Scholar
- 29.Fujisawa T, Kataoka M, Kawakami T, Isobe S, Nakajima K, Kunitomi A, et al. Pulmonary artery denervation by determining targeted ablation sites for treatment of pulmonary arterial hypertension[J]. Circ Cardiovasc Interv. 2017:10(10). https://doi.org/10.1161/CIRCINTERVENTIONS.117.005812.
- 30.Hohenforst-Schmidt W, Zarogoulidis P, Oezkan F, Mahnkopf C, Grabenbauer G, Kreczy A, et al. “Denervation” of autonomous nervous system in idiopathic pulmonary arterial hypertension by low-dose radiation: a case report with an unexpected outcome. Ther Clin Risk Manag. 2014;10:207–15. https://doi.org/10.2147/TCRM.S58705.CrossRefPubMedPubMedCentralGoogle Scholar